Oncolytics Biotech (ONCY)
Oncolytics Biotech Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ONCY related companies
ONCY News
$ONCY forms bullish "Continuation Wedge" chart pattern. http://stks.co/3mV6
about 21 days ago by RecogniaEvents
about 21 days ago by RecogniaEvents
Oncolytics Biotech (ONCY) Completes Enrollment in REOLYSIN w/ Aclitaxel and Carboplatin Phase III
Apr 02, 7:07AM Street Insider
Apr 02, 7:07AM Street Insider
$ONCY Just got 500 shares at $4.17 and plan to buy more depending on what happens in a few days from now. Hope that phase 3 trial succeeds.
about 69 days ago by Foghornreturns
about 69 days ago by Foghornreturns
$ONCY I went out to buy it at 3.91 and it jumped to $4.20 right before my very eyes. I bet if I buy it "NOW" it will go down to $2.73.
about 71 days ago by Foghornreturns
about 71 days ago by Foghornreturns
should have known people wanted to flush $ONCY to get back in the game lower and drive up
about 118 days ago by NateSays
about 118 days ago by NateSays
@EXPstocktrader has me up 10%++ for TWO DAYS IN A ROW with his picks. $ONTY $ONCY $AMLN
about 119 days ago by NateSays
about 119 days ago by NateSays
RT @a_m_f too late for entry into $ONCY $CLDX or SGMS? - I think CLDX has plenty of room...Agreed!! Great pipe= huge upside potential $CLDX
about 119 days ago by ByHighSellHigher
about 119 days ago by ByHighSellHigher
RT @a_m_f too late for entry into $ONCY $CLDX or SGMS? - I think CLDX has plenty of room. Check out their site, lots in the pipeline
about 119 days ago by DoinWerk
about 119 days ago by DoinWerk
@GArgondizza -- because I don't want to tie up that 50% when it can be in something like ....... $ONCY ... again :)
about 120 days ago by bobinaccounting
about 120 days ago by bobinaccounting
Oncolytics Biotech (ONCY) Announcs Offering of 3.57M Shares for Cdn$4.20/Share
Jan 23, 4:20PM Street Insider
Jan 23, 4:20PM Street Insider
Oncolytics (ONCY) Reports REOLYSIN Phase 2 in Combo w/ Gemzar Met Primary Endpoint
Dec 02, 7:05AM Street Insider
Dec 02, 7:05AM Street Insider
Oncolytics: positive results of U.S. Phase 2 REOLYSIN trial with Paclitaxel
Nov 14, 7:19AM FlyOnTheWall
Nov 14, 7:19AM FlyOnTheWall
Oncolytics (ONTY) Reports Positve Results from REOLYSIN Phase 2 in Advanced Head, Neck Cancer Patients
Nov 14, 7:03AM Street Insider
Nov 14, 7:03AM Street Insider
Media Advisory - Oncolytics Biotech® Inc. to Present at the JMP Securities Healthcare Conference
Sep 22, 7:00AM PR Newswire
Sep 22, 7:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ONCY | 3.40 | -0.07 | -2.02% | 265.18M |
| ONB | 11.59 | +0.03 | +0.26% | 1.092B |
| OMX | 4.88 | +0.10 | +2.09% | 413.80M |
| OMPI | 12.39 | -0.20 | -1.59% | 235.31M |
| OMN | 7.19 | +0.07 | +0.98% | 326.02M |
| OMI | 28.46 | +0.30 | +1.07% | 1.790B |
| OMG | 18.21 | -0.49 | -2.62% | 604.57M |
| SHPGY | 84.41 | -1.70 | -1.97% | 16.15B |
| SHP | 6.43 | +0.05 | +0.78% | 119.11M |
| SHOR | 4.19 | +0.17 | +4.23% | 193.64M |
